Arylalkenyl and arylalkynyl substituted imidazoquinolines
Arylalkenyl and aryalkynyl substituted imidazoquinoline compounds, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.
1. A compound of the formula (II):
wherein:
Z is —C≡C—;
X′ is —CH(R 3 )—;
R 1 is selected from the group consisting of:
—Ar and
—Ar′—Y—R 4 ;
Ar is phenyl which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, amino, alkylamino, and dialkylamino;
Ar′ is phenylene;
R 2 is selected from the group consisting of hydrogen and alkyl, wherein the alkyl group can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl and alkoxy;
Y is selected from the group consisting of:
—C(R 6 )—,
—C(R 6 )—O—,
—O—C(R 6 )—, and
—O—C(O)—O—;
R 3 is hydrogen or C 1-10 alkyl;
R 4 is selected from the group consisting of hydrogen, alkyl, and alkenyl;
R 6 is ═O; and
n is 0;
or a pharmaceutically acceptable salt thereof.
2. The compound or salt of claim 1 wherein R 2 is hydrogen, alkyl, or alkoxyalkylenyl.
3. The compound or salt of claim 2 wherein R 2 is methyl, ethyl, propyl, butyl, 2-methoxyethyl, or ethoxymethyl.
4. The compound or salt of claim 1 wherein X′ is —CH 2 —.
5. The compound or salt of claim 1 wherein R 1 is —Ar.
6. The compound or salt of claim 5 wherein R 1 is phenyl wherein the phenyl group can be unsubstituted or substituted by alkoxy, haloalkyl, halogen, nitro, or cyano.
7. The compound or salt of claim 6 wherein R 1 is phenyl, 3-chlorophenyl, 4-chlorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-trifluoromethylphenyl, or 4-trifluoromethylphenyl.
8. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 in combination with a pharmaceutically acceptable carrier.
9. The compound or salt of claim 1 , wherein the compound is 4-[3-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)-1-propynyl]benzonitrile.
10. The compound or salt of claim 1 , wherein the compound is 2-ethyl-1-(3-phenyl-2-propynyl)-1H-imidazo[4,5-c]quinolin-4-amine.
11. The compound or salt of claim 1 , wherein the compound is ethyl 4-[3-(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)-1-propynyl]benzoate.
12. The compound or salt of claim 1 , wherein the compound is 2-ethyl-1-[3-(4-methoxyphenyl)-2-propynyl]-1H-imidazo[4,5-c]quinolin-4-amine.
13. The compound or salt of claim 1 , wherein the compound is 2-ethyl-1-[3-(3-trifluoromethylphenyl)-2-propynyl]-1H-imidazo[4,5-c]quinolin-4-amine.
14. The compound or salt of claim 1 , wherein the compound is 2-ethyl-1-[3-(2-trifluoromethylphenyl)-2-propynyl]-1H-imidazo[4,5-c]quinolin-4-amine.
15. The compound or salt of claim 1 , wherein the compound is 2-ethyl-1-[3-(4-nitrophenyl)-2-propynyl]-1H-imidazo[4,5-c]quinolin-4-amine or 2-ethyl-1-[3-(3-nitrophenyl)-2-propynyl]-1H-imidazo[4,5-c]quinolin-4-amine.